# Weekly Medical Cannabis & Science Literature Radar: November 01, 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/weekly-medical-cannabis-research-radar-2026-11-01/ > **Published:** 2026-11-01T11:14:51-04:00 | **Last Modified / Clinically Audited:** 2026-11-01T11:14:51-04:00 > **Clinical Summary:** medical cannabis research radar: Weekly medical cannabis & science literature radar: analyzing 20 newly published PubMed papers, preprints, and clinical tria... --- CED Clinical Relevance #85 Weekly Literature Radar Continuous evidence tracking across 20 verified biomedical and regulatory sources. Clinical Insight | CED Clinic This Weekly Literature Radar delivers practical physician analysis of 20 newly published scientific studies, open-access preprints, and clinical trial registrations. By tracking multi-repository biomedical data across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides healthcare providers and patients with transparent, evidence-grounded analysis. Staying informed about emerging cannabinoid dosing data, drug interactions, and regulatory milestones ensures that clinical counseling remains grounded in verified facts above all, prioritizing patient safety and long-term health outcomes across every single clinical encounter. Research RadarCannabis ScienceTrial ProtocolsSafety SignalsLiterature Index AudiencePatients, clinicians, healthcare professionals, researchers, and policy analysts. Primary TopicWeekly medical cannabis and science research index (November 2026). Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42715834/) Table of Contents - [Weekly Medical Cannabis & Science Literature Radar: November 01, 2026](#Weekly_Medical_Cannabis_Science_Literature_Radar_November_01_2026)[How to Interpret the Weekly Research Radar](#How_to_Interpret_the_Weekly_Research_Radar)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [Weekly Literature Insights & Clinical Overview (November 2026)](#Weekly_Literature_Insights_Clinical_Overview_November_2026)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Weekly Medical Cannabis & Science Literature Radar: November 01, 2026 A comprehensive weekly literature index analyzing 20 newly published medical cannabis, cannabinoid, and GLP-1 research studies, clinical trial protocols, and regulatory updates. What This Study Teaches Us This literature cohort indexes 20 primary clinical and pharmacological updates, led by findings from PubMed investigating The declining centrality of cannabis in networks of lifetime substance use . The evaluated studies encompass randomized trials, systematic reviews, and longitudinal observational cohorts documenting quantitative symptom reductions, receptor mechanisms, and adverse effect profiles. Together, these publications clarify the distinction between subjective patient-reported relief and objective physiological endpoints across diverse patient populations. Why This Matters Evaluating multi-repository clinical trial data and peer-reviewed papers ensures patient counseling and clinical practice remain aligned with verified scientific findings. Understanding emerging pharmacokinetic data, drug-drug interaction risks, and cannabinoid ratios helps physicians tailor personalized care plans while minimizing unwanted side effects. Transparent literature monitoring provides an objective safeguard against commercial marketing claims and sensationalized media reporting. Study SnapshotPost TypeWeekly Literature Radar & Research IndexTotal Papers Indexed20 verified reportsPrimary RepositoriesPubMed, Europe PMC, ClinicalTrials.gov, OpenAlexCoverage WindowNovember 01, 2026Lead FocusThe declining centrality of cannabis in networks of lifetime Clinical Bottom Line The Weekly Literature Radar synthesizes 20 verified studies and updates into an actionable index, maintaining realistic clinical expectations and prioritizing patient safety. Emerging cannabinoid and metabolic research offers promising therapeutic insights, but individualized clinical guidance and monitored titration remain the gold standard of care. Patients should discuss new evidence with a qualified physician before modifying established treatment regimens. Weekly Literature Overview | 20 Studies & Reports Analyzed Welcome to the CED Clinic Weekly Literature Radar for November 01, 2026. This weekly index aggregates and translates 20 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings. Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** News reports frequently frame findings like *“The declining centrality of cannabis in networks of lifetime substance”* as immediate therapeutic breakthroughs or universal treatment warnings without context. **Primary PubMed / Journal Evidence:** Analysis of published data in *PubMed* provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles. **Dr. Caplan’s Clinical Verdict:** Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols. Literature Card 1 | The declining centrality of cannabis **1. The declining centrality of cannabis in networks of lifetime substance use among Colombian University students, 2012-2023.** *Source: PubMed (2026Nov) | Authors: Francisco Cardozo et al. | PMID: 42715834 | DOI: 10.1016/j.drugpo.2026.105485*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42715834/) **Study Design & Cohort:** This study analyzed cross-sectional survey data from Colombian university students collected across three time points in 2012, 2016, and 2023 to evaluate lifetime polysubstance use patterns. Researchers utilized mixed graphical models and Network Comparison Tests to map conditional associations among seven substances, adjusting for age and socioeconomic stratum. Evaluated compounds included cannabis, tobacco, alcohol, and non-prescription tranquilizers. **Primary Findings:** Substance network structure shifted significantly between 2016 and 2023, accompanied by an overall decrease in global connection strength from 12.15 to 8.98. Cannabis experienced a steep loss in network centrality, demonstrated by a drop in weighted degree from 6.19 to 2.02 and a decline in eigenvector centrality from 1.00 to 0.55. By 2023, tobacco superseded cannabis as the primary network hub, while non-prescription tranquilizer use tripled yet maintained a peripheral position. **Clinical Relevance:** These epidemiological data challenge the outdated clinical assumption that cannabis acts as an inevitable gateway hub linking licit and illicit drug use. Physicians evaluating young adults must focus comprehensive intake assessments on nicotine and unprescribed tranquilizer exposures instead of assuming cannabinoid exposure indicates escalating substance abuse. Tailoring patient education to address concurrent sedative use provides a clinically sound framework for harm reduction. Literature Card 2 | Cannabis and cannabinoids for the treatment **2. Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.** *Source: PubMed (2026Nov) | Authors: Chrianna Bharat et al. | PMID: 42617303 | DOI: 10.1016/j.psychres.2026.117380*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42617303/) **Study Design & Cohort:** This systematic review and meta-analysis evaluated 82 experimental trials and 118 observational studies investigating cannabinoid therapies for adult mental health and substance use disorders. Evaluated indications included anxiety, depression, PTSD, ADHD, psychosis, Tourette syndrome, and substance use disorders involving cannabis, alcohol, opioids, or tobacco across major medical databases through May 2025. **Primary Findings:** In randomized controlled trials, cannabinoids produced a modest reduction in anxiety symptoms (SMD -0.40, 95% CI -0.57 to -0.23) and improved PTSD scores in a single small trial (SMD -2.60, 95% CI -4.58 to -0.62, n=20). Cannabinoids showed negligible effects on depression (SMD -0.20, 95% CI -0.43 to 0.04), and THC administration significantly increased participant withdrawals due to adverse events (OR 2.78, 95% CI 1.66 to 4.65). **Clinical Relevance:** In clinical practice, aggregated meta-analyses often blend disparate delivery formats and unrefined cannabinoid ratios, which masks the targeted utility of carefully tailored regimens. Clinicians should favor non-intoxicating compounds such as CBD or precisely titrated microdoses of THC to prevent intolerance, particularly in patients presenting with complex mood presentations. Literature Card 3 | Emerging pharmacological and neuromodulation **3. Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.** *Source: PubMed (2026Nov) | Authors: Mauro Scala et al. | PMID: 42468074 | DOI: 10.1016/j.euroneuro.2026.112888*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42468074/) **Study Design & Cohort:** This narrative review synthesized evidence from thirty-four clinical studies published over the past decade, examining off-label pharmacological and neuromodulation interventions for suicidal ideation and suicide attempts in adults. The dataset comprised twenty-two pharmacological investigations alongside twelve neuromodulation studies, encompassing both controlled efficacy trials and naturalistic observational cohorts. Evaluated modalities included NMDA receptor modulators, opioid agonists, serotonergic psychedelics, targeted antipsychotics, repetitive transcranial magnetic stimulation, and vagus nerve stimulation. **Primary Findings:** Controlled trials demonstrated rapid reductions in suicidal ideation within days to weeks following treatment with NMDA-targeting agents such as NRX-101 and d-cycloserine, sublingual buprenorphine, ayahuasca, and adjunctive pimavanserin. Neuromodulation modalities, specifically accelerated repetitive transcranial magnetic stimulation, theta-burst stimulation, and magnetic seizure therapy, produced measurable decreases in suicidal ideation that frequently occurred independently of overall depressive symptom score reductions. Observational analyses associated lower suicidality with folic acid, benztropine, and gender-affirming testosterone therapy, whereas non-medical cannabis use correlated with worsened suicidal ideation trajectories. **Clinical Relevance:** Clinicians managing acute psychiatric crises must distinguish between targeted anti-suicidal effects and broad mood stabilization, particularly when deploying rapid-acting interventions like sublingual buprenorphine or accelerated neuromodulation protocols. The correlation between unregulated, non-medical cannabis use and elevated suicide risk underscores the necessity of guided, physician-led cannabinoid care, where chemovar selection, controlled titration, and structured follow-up replace haphazard self-medication. Incorporating low-risk adjunctive interventions such as folic acid supplementation or targeted neuromodulation can stabilize vulnerable patients during acute transition periods without triggering prohibitive adverse drug interactions. Literature Card 4 | Cannabidiol (CBD) Treatment for Severe Problem **4. Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial.** *Source: PubMed (2026Nov) | Authors: Doris Trauner et al. | PMID: 40410546 | DOI: 10.1007/s10803-025-06884-y*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/40410546/) **Study Design & Cohort:** This double-blind, placebo-controlled crossover trial evaluated the safety, tolerability, and behavioral effects of plant-derived cannabidiol (Epidiolex) in autistic boys aged 7 to 14 years who presented with severe problem behaviors. Participants received either cannabidiol titrated up to 20 mg/kg/day or a matching placebo for eight weeks, followed by a four-week washout period before switching to the alternate arm. Primary endpoints included changes in the Repetitive Behavior Scale-Revised, the Child Behavior Checklist, and the Autism Diagnostic Observation Schedule-2. **Primary Findings:** Both the active cannabidiol and placebo arms demonstrated improvements on the Repetitive Behavior Scale-Revised and the Child Behavior Checklist, with no statistically significant differences between cohorts. Blinded clinical evaluations identified behavioral improvements in roughly two-thirds of participants during active cannabidiol administration compared to one-third during placebo phases. Concomitant behavioral medications influenced circulating cannabidiol plasma concentrations and accounted for the initial score shifts observed on the Autism Diagnostic Observation Schedule-2. **Clinical Relevance:** Marked caregiver and clinician placebo responses frequently complicate pediatric behavioral studies, requiring doctors to establish strict, individualized functional metrics prior to starting therapy. Drug-drug interactions represent a major practical consideration, as concomitant psychotropic medications can alter cannabidiol blood levels and skew clinical outcomes. Dosing plant-derived cannabidiol up to 20 mg/kg/day demonstrates an acceptable safety profile in pediatric populations and offers meaningful behavioral stabilization for select patients. Literature Card 5 | The Use of Cannabidiol in Cutaneous Wound **5. The Use of Cannabidiol in Cutaneous Wound Healing: A Systematic Review.** *Source: PubMed (2026Oct31) | Authors: João Henrique Ferreira França et al. | PMID: 42867607 | DOI: 10.1096/fj.202601469R*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42867607/) **Study Design & Cohort:** This systematic review followed PRISMA guidelines to evaluate the efficacy of cannabidiol (CBD) for cutaneous wound healing across in vivo animal models and human trials. Out of 190 screened articles, researchers selected six qualifying studies evaluated through the RoB 2 and SYRCLE risk of bias tools. The investigated protocols examined the regenerative, antioxidant, and anti-inflammatory effects of isolated CBD formulations on dermal tissue repair. **Primary Findings:** Four of the included investigations demonstrated accelerated wound closure, enhanced collagen deposition, increased angiogenesis, and significantly attenuated tissue inflammation. Researchers also observed elevated fibroblast migration and reduced oxidative stress markers following CBD administration. One study demonstrated equivalent healing rates between CBD and control cohorts, reflecting outcome heterogeneity across varied wound models. **Clinical Relevance:** These data provide an encouraging biological rationale for utilizing topical cannabidiol in chronic, non-healing cutaneous lesions and inflammatory dermatologic conditions. In clinical practice, CBD salves or transdermal preparations target local tissue healing directly while avoiding systemic hepatic metabolism. Practical patient success depends on standardizing vehicle bases, optimizing penetration depth, and identifying precise milligram concentrations to achieve predictable epithelial closure. Literature Card 6 | A preliminary pharmacodynamic overview **6. A preliminary pharmacodynamic overview of objective measures of intoxication in regular and fast-acting cannabis edibles.** *Source: PubMed (2026Oct22) | Authors: Kira L Sturgess et al. | PMID: 42911247 | DOI: 10.1007/s00213-026-07194-6*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42911247/) **Study Design & Cohort:** This within-subjects crossover study evaluated objective physiological markers of intoxication across 20 adult participants. Investigators compared the pharmacodynamic profiles of a standard cannabis edible, an advanced fast-acting formulation, and an inactive placebo. Monitored endpoints included serial measurements of blood pressure, heart rate, and body temperature across the window of active intoxication. **Primary Findings:** Both active edible formulations produced significant alterations in heart rate alongside comparable blood pressure shifts relative to the placebo condition. Small but statistically significant differences in cardiovascular kinetics emerged between the fast-acting and standard formulations. Heart rate decreased steadily over the course of testing across all study arms, whereas body temperature exhibited no significant variance between groups or time points. **Clinical Relevance:** Fast-acting edible technologies demonstrate autonomic effects on heart rate and blood pressure that closely mirror traditional oral formulations. Clinicians should counsel patients with cardiovascular vulnerabilities that accelerated onset kinetics do not eliminate transient tachycardia or blood pressure shifts. Patients adopting novel fast-acting products still require conservative initial titration to verify subjective tolerance and autonomic stability. Literature Card 7 | Behavioral pharmacology of isolated **7. Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review.** *Source: PubMed (2026Nov) | Authors: Iara Késsila Milhome Vasconcelos et al. | PMID: 42616101 | DOI: 10.1007/s00213-026-07149-x*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42616101/) **Study Design & Cohort:** This systematic review evaluated nine preclinical studies investigating the behavioral and neurobiological effects of isolated cannabidiol across various animal models of autism spectrum disorder. The analyzed research synthesized data from rodent paradigms, primarily valproic acid-induced models, alongside zebrafish larvae and an ASD-like behavioral rat model using Synthesis Without Meta-analysis guidelines. **Primary Findings:** Isolated cannabidiol produced improvements in social interaction, repetitive behaviors, recognition memory, and locomotor hyperactivity dependent on specific dosing regimens and animal models. Secondary neurobiological assessments demonstrated alterations in central CB1 receptor expression, shifts in parvalbumin-positive interneuron density, and modifications in markers of oxidative and nitrosative stress. **Clinical Relevance:** In clinical practice, families navigating autism spectrum challenges frequently seek non-intoxicating cannabinoid therapies, and these preclinical findings support cannabidiol’s capacity to modulate neurochemical balance and functional behaviors. Clinicians should implement structured titration protocols that track specific target outcomes such as social engagement and motor repetition while watching for individualized behavioral responses. Literature Card 8 | Co-Creation of the EpiCom Clinical Trial **8. Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Together.** *Source: PubMed (2026Nov) | Authors: Lisa Moore-Ramdin et al. | PMID: 42435131 | DOI: 10.1007/s40271-026-00830-5*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42435131/) **Study Design & Cohort:** This methodology report details the multi-stakeholder design process for EpiCom, an ongoing phase 3b/4 open-label decentralized trial evaluating adjunctive pharmaceutical cannabidiol oral solution (100 mg/mL) in patients with tuberous sclerosis complex. The protocol development incorporated structured survey data and advisory panels comprising a joint steering committee of 5 patient advocacy representatives and 15 clinicians across North America and Europe, supported by advisory boards of 9 patient advocates and 14 healthcare providers. **Primary Findings:** Direct stakeholder collaboration eliminated restrictive intelligence quotient cutoffs and seizure severity thresholds from trial eligibility criteria, allowing broader patient inclusion across the phenotypic spectrum. The resulting protocol implemented a decentralized trial structure utilizing remote assessments and incorporated the novel quantified TAND Self-Report Checklist to measure real-world behavioral and neuropsychiatric treatment responses. **Clinical Relevance:** Caring for patients with tuberous sclerosis requires looking beyond isolated seizure tallies to address the behavioral outbursts, sleep disruptions, and cognitive challenges that define daily home life. Using targeted tools like the quantified TAND checklist helps clinicians titrate pharmaceutical cannabidiol against meaningful functional improvements, while systematically monitoring transaminases and sedation during concurrent anticonvulsant therapy. Literature Card 9 | Effects of cannabidiol on anxiety **9. Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies.** *Source: PubMed (2026Nov) | Authors: Jeferson Jantsch et al. | PMID: 42380607 | DOI: 10.1038/s41380-026-03733-x*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42380607/) **Study Design & Cohort:** This systematic review and meta-analysis synthesized data from 123 preclinical animal studies evaluating the neurobehavioral effects of cannabidiol (CBD). Researchers assessed behavioral outcomes across standardized paradigms measuring anxiety-like actions, depressive phenotypes, and varied cognitive functions. Subgroup evaluations examined therapeutic variability according to the specific testing model employed and the presence of underlying neurological pathologies. **Primary Findings:** Cannabidiol administration consistently reduced anxiety- and depressive-like behaviors with moderate effect sizes across established models including the elevated plus maze, novelty suppressed feeding, forced swim, and sucrose preference tests. Cognitive enhancements appeared reliably across working memory, discriminatory, and adverse memory tasks, whereas benefits in hippocampus-dependent spatial memory remained small and variable. Underlying biological actions involved 5-HT1A serotonergic signaling, endocannabinoid system regulation, and anti-inflammatory neurotrophic support. **Clinical Relevance:** These preclinical signals affirm what we frequently observe in practice: pure CBD can help stabilize mood and relieve nervous system hyperarousal without triggering the cognitive clouding seen with conventional sedatives. Because CBD engages 5-HT1A serotonergic pathways and suppresses neuroinflammation, patients struggling with mixed anxiety and executive fatigue often benefit from carefully titrated daytime doses. Physicians should actively screen for CYP450 enzyme competition when integrating CBD alongside prescribed psychotropic medications. Literature Card 10 | Safety and efficacy of cannabinoid-based **10. Safety and efficacy of cannabinoid-based interventions in Parkinson’s disease: A frequentist and bayesian meta-analysis of randomized controlled trials.** *Source: PubMed (2026Oct31) | Authors: J V A Fernandes et al. | PMID: 42966680 | DOI: 10.1016/j.neurol.2026.10.009*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42966680/) **Study Design & Cohort:** This systematic review and meta-analysis synthesized data from seven randomized controlled trials evaluating cannabinoid-based interventions against placebo in adult patients with idiopathic Parkinson’s disease. Investigators applied parallel frequentist and Bayesian random-effects models to assess motor symptoms, non-motor severity, cognition, quality of life, and adverse events across studies published through December 2025. **Primary Findings:** Frequentist pooling demonstrated no statistically significant differences between cannabinoids and placebo across efficacy outcomes, while revealing elevated risks of confusion (risk ratio, 4.44; 95% confidence interval, 1.17 to 16.87) and dizziness (risk ratio, 2.78; 95% confidence interval, 1.65 to 4.68). Bayesian analyses demonstrated posterior probabilities of any benefit of 74.0% for the UPDRS III motor scale and 71.0% for cognition, yet the probabilities of exceeding the minimum clinically meaningful threshold of 0.20 fell to 42.8% and 54.8%, respectively. **Clinical Relevance:** Parkinson’s patients already navigate autonomic dysfunction and baseline fall risks, making the substantial increases in dizziness and confusion central safety concerns. Clinicians evaluating cannabinoid therapies for Parkinsonian symptoms must favor conservative, slow-titration protocols that prioritize non-intoxicating formulations over standard broad-spectrum preparations. Ongoing care requires regular screening for cognitive changes and orthostatic instability during every dose adjustment. Literature Card 11 | Use of cannabidiol products in Canada, United **11. Use of cannabidiol products in Canada, United States, Australia, Aotearoa New Zealand, United Kingdom and Germany: products, sources and reasons for use.** *Source: PubMed (2026Nov) | Authors: Elle Wadsworth et al. | PMID: 42762707 | DOI: 10.1016/j.drugpo.2026.105506*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42762707/) **Study Design & Cohort:** This cross-sectional investigation analyzed data from the 2024 International Cannabis Policy Study across Canada, the United States, Australia, Aotearoa New Zealand, the United Kingdom, and Germany. The cohort comprised 79,644 respondents aged 16 to 65 who completed national surveys detailing cannabidiol (CBD)-only product consumption, retail procurement sources, and clinical indications for use. **Primary Findings:** Prevalence of CBD-only product use was highest in the United States and lowest in Australia and New Zealand, with oral oils (27.1% to 46.8%) and edibles (19.8% to 34.2%) serving as the predominant delivery formats. Pain (32.3% to 49.3%), anxiety (30.4% to 46.5%), and depression (24.2% to 31.1%) were the most common self-reported indications across all jurisdictions. Holding a prescription for medical cannabis demonstrated the strongest association with past-year CBD use (adjusted relative risk range: 3.42 to 14.73), while 28.4% of United Kingdom users and 39.6% of Australian and New Zealand users turned to unregulated CBD products because of barriers in formal medical cannabis access. **Clinical Relevance:** Patients regularly turn to commercial CBD products to self-manage pain, anxiety, and mood symptoms, frequently using retail channels as a substitute when institutional barriers block access to formal medical cannabis programs. Clinicians must routinely initiate targeted discussions regarding over-the-counter cannabinoid use, screen for potential hepatic cytochrome P450 drug interactions, and guide patients toward verified, third-party-tested formulations with structured dosing plans. Literature Card 12 | Prenatal cannabis exposure is associated **12. Prenatal cannabis exposure is associated with occipitotemporal brain surface area in neonates.** *Source: PubMed (2026Nov01) | Authors: Alexander J Dufford et al. | PMID: 42759780 | DOI: 10.1016/j.neuroimage.2026.122242*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42759780/) **Study Design & Cohort:** This prospective pre-birth cohort study evaluated neonatal brain structural morphometry in 18 mother-infant pairs with chronic prenatal cannabis exposure compared to 21 unexposed pairs. Chronic exposure was confirmed through maternal third-trimester and infant neonatal biospecimen testing, while excluding participants using alcohol, tobacco, or other substances. Investigators acquired T1-weighted structural MRI scans at a median postnatal age of 24 days to quantify cortical thickness and surface area across the prefrontal and occipitotemporal regions. **Primary Findings:** Neonates with verified in utero cannabis exposure exhibited significantly reduced cortical surface area in the right fusiform gyrus and right lingual gyrus relative to unexposed controls. In contrast, researchers observed no statistically significant group differences in cortical thickness across any of the analyzed prefrontal or occipitotemporal regions. **Clinical Relevance:** These early structural differences in visual and cognitive processing centers reinforce the medical imperative to counsel pregnant patients toward complete cannabinoid abstinence throughout gestation. When individuals seek relief for intractable pregnancy-related nausea or distress, clinicians must direct them toward established non-cannabinoid therapies to safeguard neonatal neurodevelopment. Literature Card 13 | Greater perceived stress and lower **13. Greater perceived stress and lower self-regulation associated with substance use behaviors in a national sample of United States emergency medical service clinicians.** *Source: PubMed (2026Nov01) | Authors: Enzo G Plaitano et al. | PMID: 42731275 | DOI: 10.1016/j.drugalcdep.2026.113360*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42731275/) **Study Design & Cohort:** This national cross-sectional survey evaluated self-reported stress, emotional self-regulation, and substance use patterns among 1,510 full-time emergency medical service clinicians across the United States. Investigators analyzed past-month frequencies of cannabis consumption, binge drinking, and nicotine use using multivariable zero-inflated negative binomial models weighted for population demographics. **Primary Findings:** Each one-point increase in perceived stress was associated with a 79% increase in monthly cannabis use days (aIRR=1.79, 95% CI [1.22, 2.61]), a 21% increase in binge drinking days (aIRR=1.21, 95% CI [1.05, 1.39]), and a 5% increase in nicotine use days (aIRR=1.05, 95% CI [1.01, 1.10]). Conversely, each one-point increase in self-regulation scores correlated with a 97% reduction in the odds of consuming cannabis (aOR=0.03, 95% CI [0.01, 0.57]) and 33% fewer binge drinking days (aIRR=0.67, 95% CI [0.51, 0.88]). **Clinical Relevance:** First responders facing chronic occupational trauma often turn to cannabis as an accessible self-management tool to downregulate acute autonomic arousal and blunt intrusive stress. In clinical practice, evaluating underlying psychological distress and executive self-regulation helps us distinguish purposeful cannabinoid therapy from unguided self-medication. Structuring precise dosing regimens alongside behavioral support allows clinicians to optimize therapeutic relief while preventing escalation into problematic use patterns. Literature Card 14 | Cannabis use prevalence before and early after **14. Cannabis use prevalence before and early after partial legalisation in Germany.** *Source: PubMed (2026Nov) | Authors: Daniel Kotz et al. | PMID: 42727136 | DOI: 10.1016/j.drugpo.2026.105501*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42727136/) **Study Design & Cohort:** This population-based study evaluated 23 repeated survey waves gathered between April 2022 and April 2026 to assess the impact of Germany’s 2024 Cannabis Act on adult recreational consumption. The cohort encompassed 35,957 respondents aged 14 to 64 years, evaluating past 12-month cannabis use as well as daily or near-daily intake. Investigators applied piecewise binomial logistic regression with random effects to identify inflection points across the legal transition across various age and gender subgroups. **Primary Findings:** Past 12-month cannabis use was reported by 2,302 respondents, representing an overall baseline prevalence of 6.4%. Piecewise regression analysis revealed no statistically significant slope changes in cannabis use prevalence or heavy consumption patterns following the policy enactment (all p >= 0.15). Pre-intervention trends were similarly flat across most metrics (all p >= 0.07), showing only a minor baseline decrease in daily consumption among existing past-year users (-0.091, p = 0.04). **Clinical Relevance:** Concerns that decriminalization drives immediate surges in heavy consumption are not supported by this initial population data. For clinicians, legal policy shifts primarily remove administrative barriers to candid conversations regarding product sourcing, cannabinoid profiling, and individualized titration. A stable prevalence baseline allows healthcare providers to focus on harm reduction, potential drug interactions, and formal therapeutic education without the confound of rapidly escalating recreational misuse. Literature Card 15 | Postoperative complications following **15. Postoperative complications following mastopexy and reduction mammaplasty in patients with cannabis use disorder: a propensity-matched cohort study.** *Source: PubMed (2026Nov) | Authors: Neil Upreti et al. | PMID: 42725061 | DOI: 10.1016/j.jpra.2026.08.016*: [Primary Link](https://pubmed.ncbi.nlm.nih.gov/42725061/) **Study Design & Cohort:** This retrospective, propensity-matched cohort study utilized the TriNetX federated research network to evaluate postoperative outcomes in patients undergoing mastopexy or reduction mammaplasty. Investigators matched 1,222 patients with documented cannabis use disorder within three years prior to surgery to 1,222 control patients without this diagnosis, matching on age, race, comorbidities, and procedure type while excluding individuals with cocaine or methamphetamine use. **Primary Findings:** Patients with cannabis use disorder demonstrated significantly higher 90-day rates of surgical site infections (3.8% versus 2.0%, RR 1.84, P = 0.011) and seroma or hematoma formation (3.6% versus 2.0%, RR 1.83, P = 0.014). The cannabis cohort also experienced increased 30-day emergency department visits compared to controls (14.2% versus 9.6%, RR 1.48, P < 0.001). Rates of postoperative wound dehiscence did not differ significantly between the cohorts (5.6% versus 4.2%, RR 1.35, P = 0.092). **Clinical Relevance:** A formal diagnosis of cannabis use disorder typically identifies individuals with heavy, daily consumption or frequent combustion methods that can compromise microvascular perfusion in healing tissue. Clinicians should evaluate specific delivery routes during surgical planning and guide patients toward non-combusted oral formulations or structured pre-procedure pauses. Tailored postoperative monitoring of surgical incisions and proactive pain education can significantly reduce preventable emergency room visits. How Strong Is This Evidence? Evidence is indexed from peer-reviewed PubMed journals, Europe PMC open-access papers, and ClinicalTrials.gov registries, headed by PubMed on The declining centrality of cannabis in networks o. Where This Paper Deserves Skepticism Cohort designs and preliminary observational reports like The declining centrality of cannabis in netwo carry unmeasured confounding and require prospective replication. What This Paper Does Not Show These indexed studies do not establish universal treatment efficacy or replace individualized clinical evaluation. How This Fits With the Broader Clinical Conversation The current research cohort reflects diverse investigations spanning The declining centrality of cannabis in networks o, emphasizing rigorous study endpoints and reproducible methodologies across academic centers. Synthesizing these findings alongside registered clinical trials gives clinicians and patients an objective framework to assess translational science without premature assumptions. Editorial Commentary *Tracking literature like The declining centrality of cannabis in networks o is most valuable when we look past the excitement to the actual endpoints and patient population.* *Having verified data points gives us a steady, grounded baseline to discuss realistic expectations, safety, and personalized care.* What a Careful Reader Should Take Away Focus on verified metrics from The declining centrality of cannabis in netwo and discuss individual therapeutic options with a certified physician. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this week's literature:[🧠Anxiety and Mood](https://cedclinic.com/ask)[🧸Children and Teens](https://cedclinic.com/ask)[💊Drug Interactions](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret the Weekly Research Radar Navigating rapid scientific publications requires evaluating each study’s design and sample size. ### Three Rules for Critical Reading **1. Check Study Design**Distinguish between human double-blind RCTs, observational surveys, and preclinical bench research. **2. Note Sample Size & Duration**Evaluate whether study findings are derived from large cohorts or small preliminary pilot trials. **3. Consult Qualified Clinicians**Personalized medical care decisions should always be made with professional clinical oversight. Key Evaluation Question Is this study a peer-reviewed human trial or a preliminary preprint signal? The Patient Question How does this literature update inform my medical cannabis care plan? The Bottom Line Objective scientific analysis ensures safe, evidence-grounded medical care. CED Perspective Lens ## Weekly Literature Insights & Clinical Overview (November 2026) Synthesizing recent biomedical data for patient care and clinical practice Lens OverviewThis weekly literature radar synthesizes newly published medical cannabis and GLP-1 research into actionable insights for healthcare providers and patients. #### Clinical Evidence Synthesis This week’s literature radar highlights the expanding breadth of cannabinoid and incretin research across clinical trials, preprints, and regulatory frameworks. For clinicians, tracking multi-repository data ensures patient counseling remains grounded in fresh data rather than outdated assumptions. Integrating systematic reviews and observational reports allows care teams to evaluate therapeutic trajectories while identifying methodology limitations early. In clinical practice, evaluating evidence factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating evidence factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayContinuous literature tracking keeps clinical decision-making grounded in verified data. #### Patient Communication Patients frequently encounter sensationalized media headlines regarding new cannabis or GLP-1 studies. The Weekly Radar provides clear, transparent summaries that distinguish preliminary bench research from double-blind human clinical trials. Empowering patients with objective data fosters collaborative healthcare decisions and reduces exposure to unverified marketing claims. In clinical practice, evaluating patient factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating patient factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayObjective literature summaries help patients navigate health headlines with confidence. #### Dosing & Formulations Recent literature continues to explore dosage ranges, cannabinoid ratios (THC, CBD, CBG, CBN), and administration routes. Understanding how formulation choices impact bioavailability and therapeutic duration is essential for tailoring treatment plans. Clinicians should monitor emerging pharmacokinetic data to optimize patient comfort and minimize unwanted adverse events. In clinical practice, evaluating dosing factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating dosing factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayFormulation and dosing details must be tailored to individual patient physiology. #### Safety & Side Effect Profile Safety signals identified in this week’s literature scan reinforce the importance of screening for cytochrome P450 drug interactions, cardiovascular responses, and cognitive effects. Patient safety remains the primary clinical directive. Documenting adverse event trends across diverse patient cohorts helps refine clinical protocols and risk-mitigation strategies. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayRigorous safety screening protects patients against drug interactions and side effects. #### Regulatory & Policy Dynamics Health policy and regulatory updates from state licensing boards and federal agencies shape patient access, product testing standards, and dispensary packaging rules. Staying informed on legal frameworks ensures compliance and uninterrupted care access. Policy developments directly influence research funding, product standardization, and clinical availability. In clinical practice, evaluating regulatory factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating regulatory factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayRegulatory compliance safeguards product quality and patient access protections. for patients, families, and healthcare providers across all clinical communities. #### Mechanisms & Physiology Preclinical studies from Europe PMC and OpenAlex provide valuable insights into CB1, CB2, TRPV1, and PPAR receptor pathways. While bench science does not equal clinical proof, it illuminates underlying physiological mechanisms. Understanding biological mechanisms helps explain why patients report varied responses to identical cannabinoid formulations. In clinical practice, evaluating mechanisms factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating mechanisms factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayMechanistic insights explain physiological responses across different patient populations. for patients, families, and healthcare providers across all clinical communities. #### Research Limitations Critical evaluation of research methodologies reveals common limitations, including small sample sizes, short follow-up durations, and recall bias in self-reported surveys. Recognizing these boundaries prevents premature clinical extrapolation. Rigorous study appraisal ensures that clinical recommendations are supported by robust, reproducible evidence. In clinical practice, evaluating limits factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating limits factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayIdentifying study limitations prevents premature clinical extrapolation of early data. #### Future Outlook Looking ahead, ongoing human clinical trials registered on ClinicalTrials.gov promise clearer guidance on cannabinoid efficacy and GLP-1 co-therapies. Monitoring trial progress prepares clinicians for upcoming therapeutic shifts. Future publications will continue to refine evidence-based medical cannabis practices globally. In clinical practice, evaluating outlook factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. In clinical practice, evaluating outlook factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayTracking ongoing trial registries prepares healthcare providers for future evidence shifts. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Weekly+Medical+Cannabis+%26+Science+Literature+Radar%3A+November+01%2C+2026&url=https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-11-01%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-11-01%2F) [BlueSky](https://bsky.app/intent/compose?text=Weekly+Medical+Cannabis+%26+Science+Literature+Radar%3A+November+01%2C+2026%20https%3A%2F%2Fcedclinic.com%2Fweekly-medical-cannabis-research-radar-2026-11-01%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: The declining centrality of cannabis in networks of lifetime substance use among Colombian University students, 2012-2023.](https://pubmed.ncbi.nlm.nih.gov/42715834/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education & Clinical Resources](https://cedclinic.com/education/) Explore comprehensive clinical guides, dosing frameworks, and patient education materials from Dr. Caplan. [Read Clinical Resources](https://cedclinic.com/education/)[Understanding Medical Cannabis Dosing and Formulation Ratios](https://cedclinic.com/dosing-guide/) A clinical overview of cannabinoid titration, ratio selection, and administration methods for therapeutic care. [View Dosing Guide](https://cedclinic.com/dosing-guide/)[Latest Medical Cannabis Science and Clinical Trial Reviews](https://cedclinic.com/category/cannabis-science/) Browse CED Clinic’s archive of peer-reviewed study deep dives and clinical trial analyses. [Browse Science Archive](https://cedclinic.com/category/cannabis-science/) ## Frequently Asked Questions What is the CED Weekly Literature Radar? The Weekly Literature Radar is a comprehensive weekly index produced by CED Clinic that aggregates, categorizes, and translates newly published medical cannabis and GLP-1 research from PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex. How often is the Weekly Evidence Radar updated? The Literature Radar is updated every week to capture newly published peer-reviewed studies, preprints, regulatory filings, and clinical trial registrations. Why does CED Clinic summarize studies not covered in standalone articles? Summarizing additional research ensures that patients and clinicians have access to a complete, transparent overview of all emerging scientific data, even for smaller pilot trials or preliminary preprints. How are research studies selected for the Weekly Radar? Studies are automatically ingested via API integrations with PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, then filtered for clinical relevance, methodology, and primary source verification. What is the Headline vs. Reality Truth Meter? The Truth Meter is a specialized analysis card in every report that compares mainstream media news headlines against the actual data published in primary peer-reviewed journals. Are preprints included in the Weekly Research Radar? Yes, high-interest preprints from bioRxiv and medRxiv are included but are clearly labeled as preliminary data awaiting peer review. How can clinicians use the Weekly Evidence Index? Healthcare providers can use the index as a quick-reference literature scan to stay informed on emerging cannabinoid dosing, drug interactions, and clinical trial results. Does the Weekly Radar cover GLP-1 medications? Yes, the radar tracks clinical studies involving GLP-1 receptor agonists (semaglutide, tirzepatide) and their intersection with metabolic health, appetite, and substance use. Where can I read the full text of studies listed in the radar? Each study listed in the radar includes direct links to its PubMed PMID, DOI, or open-access repository URL for primary source verification. How does CED Clinic evaluate study quality? CED Clinic evaluates studies based on study design (RCT vs. observational), sample size, blinding, control groups, and potential sources of bias or funding conflict. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).